ClinicalTrials.gov
ClinicalTrials.gov Menu

Contrast Sensitivity in Glaucoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00947869
Recruitment Status : Unknown
Verified July 2009 by University of Erlangen-Nürnberg Medical School.
Recruitment status was:  Recruiting
First Posted : July 28, 2009
Last Update Posted : July 28, 2009
Sponsor:
Information provided by:
University of Erlangen-Nürnberg Medical School

Brief Summary:
The primary aim of the Erlangen´s Glaucoma Contrast Sensitivity-Study (EGCS-Study) is the evaluation of the diagnostic and prognostic validity of a diagnostic procedure, measuring contrast sensitivity. No therapeutic studies are performed.

Condition or disease
Primary Open Angle Glaucoma Secondary Open Angle Glaucoma Due to PEX

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)
Study Start Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic
Criteria
  • Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX
  • Healthy volunteers (for reliability analysis)

Inclusion Criteria:

  • Age > 18
  • Best corrected visual acuity 0.8 or better
  • European

Exclusion Criteria:

  • eye diseases: Infantile glaucoma, angle glaucoma, secondary open angle glaucoma, wich are not due to PEX, diseases involving retina, condition after ophthalmological operations or trauma, cataract, diseases concerning the refractive system, age-related macular degeneration, diabetic retinopathy, optic neuropathy (MS, neuritis), amblyopia
  • Any neurological diseases
  • Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus)
  • Systemic drugs with potentially ocular involvement
  • ocular drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00947869


Contacts
Contact: Anselm G Juenemann, Prof. anselm.juenemann@uk-erlangen.de

Locations
Germany
University Eye Hospital Recruiting
Erlangen, Bavaria, Germany, 91054
Contact: Hohberger    **49-9131-8534521      
Sponsors and Collaborators
University of Erlangen-Nürnberg
Investigators
Study Chair: Anselm G Juenemann, Prof. University Erlangen-Nuremberg

Responsible Party: University Eye Hospital Erlangen, University of Erlangen-Nürnberg
ClinicalTrials.gov Identifier: NCT00947869     History of Changes
Other Study ID Numbers: DFG-SFB539-H
First Posted: July 28, 2009    Key Record Dates
Last Update Posted: July 28, 2009
Last Verified: July 2009

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases